Background on Colorectal Cancer Screening and its Role in Patient Care

Opinion
Video

Arvind Dasari, MD, MS, outlines the evolution of colorectal cancer screening, addressing historical challenges, and the development of non-invasive screening techniques.

  1. Dr Dasari: Please describe the importance and a brief history of CRC screening
    1. What are some challenges traditionally associated with CRC screening?
      1. Do these challenges vary between academic and community settings?
    2. How have noninvasive screening methods and age recommendations evolved over time?
      1. Please briefly mention the variety of sources (stool, blood, tissue, etc.) and methods that have become available
Recent Videos
4 experts in this video
4 experts in this video
Future research will aim to assess the efficacy of PIPAC-MMC plus systemic therapy vs systemic therapy alone in patients with peritoneal tumors.
Although small incision surgery may serve as a conduit to deliver PIPAC-MMC, it may confer benefits in the staging and treatment of peritoneal tumors.
Patients with peritoneal metastases were historically associated with limited survival and low consideration for clinical trials.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
3 experts are featured in this series.
Related Content
HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

HIPEC Does Not Add Benefit to Cytoreduction Surgery in CRC Peritoneal Metastasis

Tim Cortese
March 31st 2025
Article

Muhammed Talha Waheed, MD, stated that a retrospective study found an OS benefit in CRC peritoneal metastasis with cytoreduction surgery without HIPEC vs with HIPEC.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

Sirexatamab Combo Shows Positive Activity in Advanced MSS Colorectal Cancer

Russ Conroy
March 31st 2025
Article

Sirexatamab plus bevacizumab/chemotherapy significantly improved overall response rate in patients with high DKK1 levels in the phase 2 DeFianCe study.

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

Jagoda Misniakiewicz, PharmD
June 10th 2024
Podcast

Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.

Suvemcitug Combination Therapy Exhibits Safety, Activity in MSS/pMMR CRC

Roman Fabbricatore
March 2nd 2025
Article

In a small cohort of patients with MMS/pMMR CRC, the suvemcitug and envafolimab pharmacokinetic profiles were comparable with prior monotherapy studies.

Phase 3 CheckMate-8HW trial results evaluating the combination in microsatellite instability–high or mismatch repair deficient CRC supported the decision.

FDA Grants Priority Review to Nivolumab/Ipilimumab in MSI-H/dMMR CRC

Roman Fabbricatore
February 24th 2025
Article

Phase 3 CheckMate-8HW trial results evaluating the combination in microsatellite instability–high or mismatch repair deficient CRC supported the decision.